Oligoprogression in Non-Small Cell Lung Cancer

We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daijiro Harada, Nagio Takigawa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	non-small cell lung cancer oligometastatic disease oligoprogressive disease driver mutations tyrosine kinase inhibitor immune checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8a9c547006e546d2b1c06ebecb252fe7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a9c547006e546d2b1c06ebecb252fe7
record_format	dspace
spelling	oai:doaj.org-article:8a9c547006e546d2b1c06ebecb252fe72021-11-25T17:04:26ZOligoprogression in Non-Small Cell Lung Cancer10.3390/cancers132258232072-6694https://doaj.org/article/8a9c547006e546d2b1c06ebecb252fe72021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5823https://doaj.org/toc/2072-6694We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing the same anticancer agents beyond progressive disease after LAT with radiation therapy for OPD are based on the concept of progression in which only a small number of lesions, not more than about four, proliferate after chemotherapy. In the case of OPD harboring driver mutations such as EGFR, prospective studies are underway. However, evidence from retrospective studies support this strategy, which is currently recommended in some guidelines. The prognosis in OPD cases during the administration of an immune checkpoint inhibitor (ICI) is relatively promising. Additionally, LAT with radiation for OPD after the first-line treatment of ICI with cytotoxic chemotherapy may overcome the resistance to the combination drug therapy due to an abscopal effect. To achieve long-term survival in advanced-stage NSCLC, it is important to verify the optimal method and timing of the therapy through prospective comparative studies as well as patient selection based on patient characteristics and biomarker levels.Daijiro HaradaNagio TakigawaMDPI AGarticlenon-small cell lung canceroligometastatic diseaseoligoprogressive diseasedriver mutationstyrosine kinase inhibitorimmune checkpoint inhibitorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5823, p 5823 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer oligometastatic disease oligoprogressive disease driver mutations tyrosine kinase inhibitor immune checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer oligometastatic disease oligoprogressive disease driver mutations tyrosine kinase inhibitor immune checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Daijiro Harada Nagio Takigawa Oligoprogression in Non-Small Cell Lung Cancer
description	We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing the same anticancer agents beyond progressive disease after LAT with radiation therapy for OPD are based on the concept of progression in which only a small number of lesions, not more than about four, proliferate after chemotherapy. In the case of OPD harboring driver mutations such as EGFR, prospective studies are underway. However, evidence from retrospective studies support this strategy, which is currently recommended in some guidelines. The prognosis in OPD cases during the administration of an immune checkpoint inhibitor (ICI) is relatively promising. Additionally, LAT with radiation for OPD after the first-line treatment of ICI with cytotoxic chemotherapy may overcome the resistance to the combination drug therapy due to an abscopal effect. To achieve long-term survival in advanced-stage NSCLC, it is important to verify the optimal method and timing of the therapy through prospective comparative studies as well as patient selection based on patient characteristics and biomarker levels.
format	article
author	Daijiro Harada Nagio Takigawa
author_facet	Daijiro Harada Nagio Takigawa
author_sort	Daijiro Harada
title	Oligoprogression in Non-Small Cell Lung Cancer
title_short	Oligoprogression in Non-Small Cell Lung Cancer
title_full	Oligoprogression in Non-Small Cell Lung Cancer
title_fullStr	Oligoprogression in Non-Small Cell Lung Cancer
title_full_unstemmed	Oligoprogression in Non-Small Cell Lung Cancer
title_sort	oligoprogression in non-small cell lung cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8a9c547006e546d2b1c06ebecb252fe7
work_keys_str_mv	AT daijiroharada oligoprogressioninnonsmallcelllungcancer AT nagiotakigawa oligoprogressioninnonsmallcelllungcancer
_version_	1718412726389178368

Oligoprogression in Non-Small Cell Lung Cancer

Ejemplares similares